Semax for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Semax for Health & Longevity

Created on 07/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A Russian-developed nasal peptide built from a stress-hormone fragment but stripped of hormonal action, best known for raising a brain-growth protein and used for focus, memory, and stroke recovery. Mechanistically credible and regionally established, but not independently proven: nearly all human evidence is single-country, longevity claims rest on animal data, and long-term safety is unknown. (Full Review)

Protocol

Dose & Route
250–1,200 mcg/day intranasal
0.1% (1 mg/mL) solution, split into 1–3 applications
Timing
Morning to early afternoon
Activating; avoid late-day dosing to protect sleep
Course & Cycling
10–14 day courses
Cycle with breaks rather than continuous daily use
Time to effect
Stroke Recovery
Over a course of days
Adjunctive recovery; earlier post-onset dosing favored
Focus & Memory
Minutes to a few hours
Acute cognitive and focus effects per dose
Mood & Neuroprotection
Builds over days
No durable long-term change from short-term use

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Children (outside Russian pediatric approvals under medical supervision)
  • Uncontrolled psychiatric conditions sensitive to stimulation
  • Inability to obtain pharmaceutical-grade, verified product
  • Not a substitute for emergency care in acute neurological conditions (e.g., stroke)
    •
Key Interactions
  • Stimulants and activating compounds (caffeine, amphetamine, methylphenidate, modafinil)
  • Serotonergic medications (SSRIs, SNRIs, such as sertraline, venlafaxine)
  • Dopaminergic medications (levodopa, dopamine agonists)
  • OTC decongestant nasal sprays (oxymetazoline, phenylephrine) and intranasal steroids
  • Other nootropic or peptide supplements (Selank, Noopept, racetams)
  • Anticoagulants
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: [risks_medium]
    •
  • Low: Local nasal irritation and discomfort; headache and overstimulation
    •
  • Speculative: Unknown long-term safety outside the Russian record; product quality, contamination, and immunogenicity risk; theoretical effects from melanocortin and monoamine activity
    •

Monitoring

Marker Target Why
Resting blood pressure ~110–125 / 70–80 mmHg Screen for and track any activation-related change
Resting heart rate ~55–75 bpm Detect overstimulation from activating effects
BDNF (serum) Higher-normal for assay used Track the peptide's main proposed mechanism as a response marker
hs-CRP < 1.0 mg/L General health and inflammatory-status context
Sleep quality (wearable or diary) Stable/improved vs. baseline Catch dosing-timing-related sleep disruption

Cadence: Baseline before starting, review after the first 1–2 week course, then every 3–6 months if continuing.

Qualitative Assessment

  • Focus, mental clarity, and task persistence during the day
  • Working-memory and recall performance in daily tasks
  • Mood, motivation, and stress resilience
  • Sleep onset and sleep quality (to catch late-dosing effects)
  • Local nasal comfort and absence of persistent irritation or discoloration
  • Absence of jitteriness, restlessness, or "over-activated" feeling
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.